Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07731425) titled 'Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival' on July 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: London School of Economics and Political Science
Condition:
Cancer
Intervention:
Other: FDA explanation for progression-free survival (control)
Other: FDA explanation for progression-free survival with overall survival data
Other: NCI explanation for progression-free survival
Other: ...